| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | E1192-E1206 |
| Publicación | CMAJ |
| Volumen | 190 |
| N.º | 40 |
| DOI | |
| Estado | Published - oct. 9 2018 |
| Publicado de forma externa | Sí |
Nota bibliográfica
Funding Information:Funding: Funding for the development of the 2018 C-CHANGE guideline was provided by the Canadian Vascular Network through a Canadian Institutes of Health Research Emerging Networks Grant (no. 132211). The C-CHANGE implementation tools and activities were funded by the Public Health Agency of Canada (no. 6464-15-201-8041132) and the Ontario Ministry of Health and Long-Term Care (no. 06668 and 0669). The funders did not have a direct influence on the process, the contents of the recommendations or the preparation of the manuscript.
Funding Information:
Competing interests: Todd Anderson reports receiving grants from Amgen and DalCor, and personal fees from Sanofi, Merck, and Amgen, outside the submitted work. Alice Cheng reports personal fees from Abbott, Boehringer Ingel-heim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Servier and Takeda, outside the submitted work. Gord Gubitz reports receiving personal fees from Bayer, Pfizer and Boehringer Ingelheim, outside the submitted work. David Lau reports receiving research funding and speaker fees from AstraZeneca and Novo Nordisk and has received speaker fees and/or served as consultant from Amgen, Akcea, Boehringer Ingelheim, Janssen, Merck, Shire and Valeant, outside the submitted work. Lawrence Leiter has received research funding from, has provided CME on behalf of, or has acted as an adviser to Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Esperion, GlaxoSmithKline, Janssen, Kowa, the Medicines Company, Merck, Novartis, Novo Nordisk, Res-verlogix, Sanofi, Servier and The Medicines Company, outside the submitted work. Peter Selby reports receiving grants from Pfizer Inc., Bhasin Consulting Fund, Patient-Centered Outcomes Research Institute, Pfizer Canada Inc.; personal fees from Bristol-Myers Squibb, Pfizer Canada Inc., Evidera Inc., Johnson & Johnson Group of Companies, Medcan Clinic, Miller Medical Communications, NVision Insight Group, Myelin & Associates; and is a vendor of record for providing smoking cessation pharmacotherapy (free or discounted) for research studies for Pfizer, Novartis, Johnson & Johnson, and Med-Plan Communications, outside the submitted work. Simon Bacon has received consultancy fees from Schering-Plough, Merck and Sygesa, speaker fees from Novartis, and investigator-initiated grants from GlaxoSmithKline and AbbVie. Sheldon Tobe reports grants from Eli Lilly, Astra Zeneca, AbbVie and Bayer, as well as personal fees from Servier and Valeant, during the conduct of the study. He has also had travel reimbursed by the Novartis Foundation. Sean Wharton reports personal fees from Novo Nordisk, Janssen and Eli Lilly, outside the submitted work. Eileen O’Meara reports clinical trial and national leader function fees paid to her institution from Novartis; clinical trial and national leader function fees paid to her instution, as well as consulting fees from Astra Zeneca; clinical trial fees paid to her institution from Merck; clinical trial fees paid to her institution and consulting fees from Bayer; and clinical trial and steering committee fees paid to her institution from Amgen. James Stone reports personal fees from Astra Zeneca, Bayer, Lilly, Sanofi, Novo-Nordisk and Servier, as well as personal fees for a clinical research trial from Sanofi, outside the submitted work. No other competing interests were declared.
Funding Information:
Funding for the C-CHANGE consensus conference and administrative support came from the Canadian Institutes of Health Research and in-kind support from the scientific and professional volunteers engaged in the process.
ASJC Scopus Subject Areas
- General Medicine
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
